Study Evaluating the Association of Antibiotic Measures and Control of Bacterial Resistance

Wyeth is now a wholly owned subsidiary of Pfizer335 enrolled

Overview

Assess efficacy of piperacillin/tazobactam in reducing the cases of colonization and infection of bacteria.

Primarily, this study is designed to assess the efficacy of piperacillin/tazobactam in reducing the cases of colonization and infection of extended-spectrum betalactamases (ESBLs) producing E.coli or K pneumoniae, S aureus methicillin resistant (MRSA) and Enterococcus vancomycin resistant (VRE). Secondly, this study plans to determine the acquisition rate of ESBL producing E Coli or K pneumoniae, methicillin resistant S Aureus (MRSA) and vancomycin resistant Enterococcus spp (VRE), both pre- and post-intervention.

Study Type

OBSERVATIONAL

Enrollment

335

Conditions

Bacterial Infections

Eligibility

Sex: ALL

Medical Language ↔ Plain English

All patients admitted in ICU will be enrolled (who qualify for treatment).

Outcomes

Primary Outcomes

Endpoints will be efficacy of piperacillin/tazobactam in reducing colonization rates and infection of E coli or K pneumoniae, vancomycin resistant enterococcus and methicillin resistant S aureus

Time frame: 8 months

Secondary Outcomes

Endpoints will be acquisition and infection rate of ESBL producing E coli or K pneumoniae, vancomycin resistant enterococcus and methicillin resistant S aureus

Time frame: 8 months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.